ASCO 2015 | Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
Thomas Powles
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer.
Related videos
1:26 Comparison of investigator-initiated and industry-initiated trials by Dr Sridhar
Srikala Sridhar
3:25 Enfortumab vedotin as treatment for urothelial carcinomas
Daniel Petrylak
2:53 Issues surrounding patient-centered outcomes in the genitourinary field
John Gore
1:51 The evolving first-line treatment landscape for advanced RCC
Rana McKay
1:10 Key bladder cancer updates from ASCO GU 2019
Brant Inman
